Takeda Pharmaceutical Co. (NYSE:TAK) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC boosted its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 22.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,042 shares of the company’s stock after buying an additional 1,296 shares during the period. GAMMA Investing LLC’s holdings in Takeda Pharmaceutical were worth $105,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TAK. Bank of New York Mellon Corp boosted its stake in Takeda Pharmaceutical by 17.2% during the fourth quarter. Bank of New York Mellon Corp now owns 104,892 shares of the company’s stock worth $1,389,000 after buying an additional 15,388 shares during the last quarter. US Bancorp DE boosted its stake in Takeda Pharmaceutical by 21.2% during the fourth quarter. US Bancorp DE now owns 124,332 shares of the company’s stock worth $1,646,000 after buying an additional 21,744 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Takeda Pharmaceutical by 35.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 253,551 shares of the company’s stock worth $3,357,000 after buying an additional 66,386 shares during the last quarter. Assetmark Inc. boosted its stake in Takeda Pharmaceutical by 6.4% during the fourth quarter. Assetmark Inc. now owns 86,167 shares of the company’s stock worth $1,141,000 after buying an additional 5,185 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Takeda Pharmaceutical during the fourth quarter worth $1,447,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $15.55 on Monday. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.53. The business’s fifty day simple moving average is $14.87 and its 200-day simple moving average is $14.33. The firm has a market cap of $49.48 billion, a PE ratio of 70.69 and a beta of 0.23. The company has a quick ratio of 0.52, a current ratio of 1.01 and a debt-to-equity ratio of 0.57.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. The business had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Equities analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.